Literature DB >> 11815746

Unilateral spinal anesthesia. State of the art.

A Casati1, G Fanelli.   

Abstract

The possibility to control the spread of intrathecal drugs, restricting the distribution of spinal block to the operated side is still controversial. Various authors reported that we can not predict the distribution of spinal block; however, other authors described how to restrict spinal block at the operated side in patients receiving surgical procedures involving one lower limb. Therefore, we reviewed clinical studies on this topic trying to outline the feasibility and potential clinical benefits of unilateral spinal anesthesia. The main results of studies recently published on peer reviewed journals concerning the clinical use of unilateral spinal anesthesia are reviewed. The main factors we must consider when attempting a unilateral spinal block are the use of small doses of local anesthetic solution injected through directional, pencil-point needles, together with a 15-20 min lateral decubitus position and the use of either hypo- or hyperbaric anesthetic solution. Using 6-8 mg of either hyper- or hypobaric bupivacaine provides a unilateral distribution of sympathetic and sensory blocks in 50 to 70% of patients, while unilateral motor block can be observed in up to 80% of cases. Attempting a unilateral spinal block results in a four-fold reduction in the incidence of clinically relevant hypotension with more stable cardiovascular parameters as compared with conventional bilateral spinal block. The small amount of local anesthetic solution injected, as well as the reduced extent of spinal block, also provide a favourable profile of the resolution of spinal block, which can be useful in the ambulatory setting. With simple technical skill we can reliably provide a preferential distribution of spinal block to the operated side. This results in a minimal delay in preparation time, but provides less hemodynamic side effects with higher cardiovascular stability, and increased autonomy after surgery with better patient acceptance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11815746

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  7 in total

1.  Characteristics of unilateral spinal anesthesia at different speeds of intrathecal injection.

Authors:  Yilmaz Apaydin; Gulcan Erk; Ozlem Sacan; Civan Tiryaki; Vildan Taspinar
Journal:  J Anesth       Date:  2011-05-26       Impact factor: 2.078

Review 2.  [Unilateral spinal anesthesia : Literature review and recommendations].

Authors:  B Büttner; A Mansur; M Bauer; J Hinz; I Bergmann
Journal:  Anaesthesist       Date:  2016-11       Impact factor: 1.041

3.  Do we still need to restrict preoperative fluid administration in ambulatory anorectal surgery under spinal anaesthesia?

Authors:  B C Orbey; Z Alanoglu; A A Yilmaz; B Erkek; Y Ates; M Ayhan Kuzu
Journal:  Tech Coloproctol       Date:  2009-03-14       Impact factor: 3.781

4.  Comparison of Intraoperative and Postoperative Effects of Lateral Epidural and Midline Epidural Anaesthesia in Patients Undergoing Unilateral Lower Extremity Operation.

Authors:  Başak Tırak Boyacı; Dilek Erdoğan Arı; Tülay Tunçer Peker; Barbaros Baykal
Journal:  Turk J Anaesthesiol Reanim       Date:  2015-02-16

5.  Effect of spinal flexion and extension in the lateral decubitus position on the unilaterality of spinal anesthesia using hyperbaric bupivacaine.

Authors:  Shrinivas Kulkarni; C L Gurudatt; Deepika Prakash; Jincy A Mathew
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2018 Oct-Dec

6.  Optimal dose of hyperbaric bupivacaine 0.5% for unilateral spinal anesthesia during diagnostic knee arthroscopy.

Authors:  Hm Atef; Am El-Kasaby; Ma Omera; Md Badr
Journal:  Local Reg Anesth       Date:  2010-08-26

7.  Comparison of two doses of hypobaric bupivacaine in unilateral spinal anesthesia for hip fracture surgery: 5 mg versus 7.5 mg.

Authors:  Mohamed Kahloul; Mohamed Said Nakhli; Amine Chouchene; Nidhal Chebbi; Salah Mhamdi; Walid Naija
Journal:  Pan Afr Med J       Date:  2017-10-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.